Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label secukinumab in Japanese patients with generalized pustular psoriasis
jRCT2080222256Phase 3
- Sponsor
- Novartis
- Start
- Oct 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of secukinumab in generalized pustular psoriasis (GPP), sponsored by Novartis.
02
Drugs
secukinumab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on jRCT2080222256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222256.